X
Xinhanglu Medical Technology (Guangzhou)
Cardiac technology company advancing electrophysiology with next-gen mapping and integrated PFA platform for heart rhythm patients
About Xinhanglu Medical Technology (Guangzhou)
EnChannel Medical, founded in 2020, is a cardiac technology company headquartered in Guangzhou, China, with a subsidiary in Irvine, CA. The company specializes in developing advanced electrophysiology solutions, focusing on a next-generation mapping system and an integrated Pulsed Field Ablation (PFA) platform. EnChannel Medical aims to enhance the quality of life for patients with complex cardiac arrhythmias by providing intuitive, safer, and more effective personalized solutions. The company serves the global healthcare market, targeting medical professionals and institutions dealing with heart rhythm disorders. EnChannel Medical operates on a business model that combines cutting-edge technology with clinical expertise to deliver high-value medical devices. Revenue is generated through the sale of these specialized cardiac solutions. The leadership team, including CEO and Co-Founder Jun Feng, brings over 30 years of experience in clinical medical work, medical technology marketing, and high-tech consumable sales.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 34
- Open positions
- None listed
- Dealroom signal
- 88.3/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- medical implants, Surgery, Cardiology and cardiovascular, Surgical Equipment, DT and LS, science-based
- Technology
- Deep Tech
- Client focus
- B2B
- Investment activity
- 1 company, latest Jul 2025
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | May 2025 | $83M | $330M | Lilly Asia Ventures · Lapam Capital · Dragonball Capital | ↗ |
| SERIES AOther financing | Aug 2023 | $28M | $110M | Lilly Asia Ventures · Longpan Investment | ↗ |
Growth signals
Latest recorded traffic for Xinhanglu Medical Technology (Guangzhou) is 1.7K monthly website visits, up 193.1% over the last three months. Xinhanglu Medical Technology (Guangzhou)'s team grew 30.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Xinhanglu Medical Technology (Guangzhou) in the Ladera Ranch ecosystem
The Xinhanglu Medical Technology (Guangzhou) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Lilly Asia Ventures- LILongpan Investment
Dragonball Capital
Lapam Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Xinhanglu Medical Technology (Guangzhou) on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Xinhanglu Medical Technology (Guangzhou)’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









